Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) rose 6.7% during trading on Friday . The stock traded as high as $22.39 and last traded at $22.32, with a volume of 2,001,453 shares traded. The stock had previously closed at $20.92.

SRPT has been the subject of several research reports. Royal Bank Of Canada restated a “hold” rating and set a $5.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 3rd. William Blair cut shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, April 21st. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target for the company in a report on Thursday, June 2nd. Robert W. Baird restated an “outperform” rating and set a $23.00 price target on shares of Sarepta Therapeutics in a report on Thursday, May 26th. Finally, Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $60.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $24.17.

The company’s market cap is $1.04 billion. The company has a 50-day moving average price of $19.11 and a 200-day moving average price of $19.13.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, May 5th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.15. During the same period in the prior year, the business earned ($1.15) EPS. On average, equities research analysts predict that Sarepta Therapeutics Inc. will post ($4.54) EPS for the current year.

A number of institutional investors have made changes to their positions in SRPT. Jennison Associates LLC raised its position in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock worth $32,354,000 after buying an additional 689,831 shares in the last quarter. Mutual of America Capital Management LLC raised its position in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Sarepta Therapeutics by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $1,725,000 after buying an additional 5,300 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Sarepta Therapeutics by 20.5% in the fourth quarter. ProShare Advisors LLC now owns 42,922 shares of the company’s stock worth $1,656,000 after buying an additional 7,301 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its position in shares of Sarepta Therapeutics by 7.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 139,145 shares of the company’s stock worth $5,368,000 after buying an additional 9,765 shares in the last quarter.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.